Form 4: Acumen Pharmaceuticals CEO Sells Shares to Cover Tax Obligations

Acumen Pharmaceuticals CEO, Daniel Joseph O'Connell, sold 12,619 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Daniel Joseph O'Connell, CEO of Acumen Pharmaceuticals, sold 12,619 shares of common stock on January 21, 2025.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $1.593, with individual transactions ranging from $1.5700 to $1.6100.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 24, 2024.
• Following the transaction, O'Connell directly owns 667,488 shares of Acumen Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any new material non-public information.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are common across the industry.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.
• Similar transactions are regularly reported by executives at comparable biotech companies such as Biogen, Amgen, and Regeneron.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Acumen Pharmaceuticals, stock sale, insider trading, Rule 10b5-1, CEO, Daniel Joseph O'Connell, tax obligations, restricted stock units